UniQure Continues FDA Clash Over AMT-130 Huntington's Pathway. Following the Type A meeting in January, FDA maintains that Phase I/II data with external controls are insufficient for a marketing application and strongly recommends a sham-controlled Phase III. UniQure plans a Type B meeting in Q2 2026 to discuss trial design. The European pathway via conditional approval remains a potential alternative. The regulatory stance reinforces heightened evidentiary standards for CNS gene therapies established in recent months.

Voyager's VY1706 Tau-Silencing Gene Therapy on Track for IND Q2 2026. GLP toxicology study completion expected Q1 2026. In NHP studies, a single IV dose achieved 50-73% tau mRNA reduction across the cerebral cortex. If IND is accepted, first-in-human dosing is targeted for H2 2026 — making this one of only two IV-delivered CNS gene therapies (alongside Neurocrine/Voyager's GBA1 program) expected to enter the clinic this year.

Ublituximab Demonstrates Sustained 5-Year Efficacy in MS Open-Label Extension. Annualized relapse rates continued to decline through year 5 (0.04 vs 0.08 at year 1) in a JAMA Neurology publication. TG Therapeutics' data strengthen Briumvi's positioning against Ocrevus biosimilars at $72,000 annual pricing, though biosimilar projections at $45K-$55K create commercial headwinds requiring differentiation on convenience or outcomes.

Regeneron Cemdisiran US Filing Planned Q1 2026 for Myasthenia Gravis. The quarterly subcutaneous siRNA targeting complement C5 met all primary and key secondary endpoints in the Phase 3 NIMBLE trial, achieving 2.3-point placebo-adjusted improvement in MG-ADL scores with ~74% complement inhibition as monotherapy. The filing sets up a direct competitive confrontation with argenx's Vyvgart (FcRn blocker) and AstraZeneca's Ultomiris (long-acting C5 mAb).

CGRP Cardiovascular Signal Continues to Generate Payer and Prescriber Attention. Phase 4 TRIUMPH study data (Headache) show galcanezumab outperforming traditional oral preventives in real-world settings, while the separate US cohort study (900,000+ patients, aHR 1.3 composite CV events) drives risk-benefit discussions. The American Headache Society maintains first-line preventive status for CGRP drugs, but payers may begin incorporating cardiovascular screening into prior authorization for chronic migraine populations.

Vima Launches With $100M to Develop Oral Movement Disorder Drugs. Atlas Venture-backed Vima targets dystonia and Parkinson's disease with daily oral formulations addressing dopaminergic dysfunction. The well-capitalized startup enters a crowded space against AbbVie's tavapadon (NDA under review), Bayer's bemdaneprocel (Phase 2 stem cell therapy), and NeuroDerm's ND0612 (approved subcutaneous levodopa). Differentiation will depend on mechanism selectivity and motor fluctuation profiles beyond the D1/D5 and dopamine replacement paradigms.

Alzheimer's Tau Pipeline Consolidates Around Three Modality Leaders. Voyager's APOE pause and continued tau investment underscores the field's conviction that tau, not APOE or amyloid alone, is the key to meaningful disease modification. Three modalities now compete head-to-head: anti-tau antibodies (Voyager VY7523, BMS etalanetug + Leqembi combo, Lilly pipeline), tau-silencing gene therapy (Voyager VY1706, IND Q2 2026), and tau ASOs (Biogen BIIB080/CELIA trial). The emerging anti-amyloid + anti-tau combination paradigm — etalanetug's Fast Track for use alongside Leqembi — could reshape the commercial landscape from single-agent competition to regimen-based positioning, echoing the oncology combination model.

BTK Inhibitor Commercial Outlook Hinges on Liver Safety and Payer Step-Edits. Sanofi's tolebrutinib CRL and fenebrutinib's prior FDA clinical hold for liver enzyme elevations establish hepatotoxicity as the class-defining regulatory concern. Early prescriber feedback from the tolebrutinib CRL fallout indicates neurologists increasingly prefer to wait for fenebrutinib's anticipated broader label (RMS + PPMS). Commercial forecasts project a $12-15B combined BTK market by 2030, but the payer landscape is evolving: step-edit requirements mandating anti-CD20 therapy failure before BTK access could limit initial penetration and favor companies with established MS infrastructure and nurse educator networks.

Myasthenia Gravis Market Enters Four-Way Platform Competition. Regeneron's imminent cemdisiran filing (quarterly SC siRNA) joins argenx Vyvgart (weekly SC FcRn blocker, approved gMG + CIDP), AstraZeneca Ultomiris (Q8W IV C5 mAb, CHAMPION-NMOSD zero relapses in 58 patients), and Amgen Uplizna (twice-yearly SC CD19 depletion, EC-approved Feb 2026 for gMG). Dosing frequency becomes the key commercial differentiator: Regeneron's quarterly dosing and Amgen's twice-yearly maintenance could pressure argenx's weekly regimen, though Vyvgart's first-mover data depth and dual gMG/CIDP label provide a defensive moat.

Rare Neurology M&A Accelerates as Big Pharma Scouts Orphan Assets. Lundbeck's accelerated MSA trial positions the company as an acquisition target with precedent valuations suggesting $8-12B enterprise value if Phase 3 succeeds. Potential buyers include Takeda (seeking neurology re-entry after $4.8B Entyvio biosimilar exposure 2027-2029), Otsuka (pipeline rebuild beyond Abilify generics), and Jazz (rare neurological franchise aggregation). Separately, Evotec's 800-person workforce reduction signals contraction in early-stage neuroscience investment, creating acqui-hire opportunities for well-capitalized biotechs.

PBM Pricing Pressure Intensifies Across High-Cost Neurology Therapeutics. 2026 formulary negotiations incorporate CMS Maximum Fair Price provisions, with exposed franchises including Biogen's Alzheimer's portfolio (Leqembi facing 28% price reduction demands), rare disease gene therapies (BioMarin's Roctavian encountering access barriers at $2.9M), and MS anti-CD20s where biosimilar competition drives 40-55% discounts. Manufacturers with value-based agreements and outcomes data gain relative formulary positioning advantage.

Q2 2026 Becomes the Pivotal Quarter for Tau and Parkinson's. Voyager's VY1706 IND filing, AbbVie's tavapadon PDUFA decision, and Eisai's Leqembi weekly SC dosing decision all converge in Q2. The tau landscape will be further shaped by third-party data readouts from BMS (etalanetug + Leqembi Phase 2/3) and Biogen (BIIB080 CELIA trial updates), which will inform whether the industry accelerates toward combination anti-amyloid + anti-tau regimens as the standard of care in Alzheimer's.

Fenebrutinib Filing Expected to Establish BTK Regulatory Template. Roche's anticipated H1 2026 submission across both RMS and PPMS will be the first BTK filing in MS since Sanofi's CRL, and FDA's handling will signal whether the class can overcome liver safety concerns. The FENhance data presentation at AAN (April 2026) will be the definitive competitive comparison event for neurologists evaluating the BTK class versus established anti-CD20 therapies.

PACAP Pipeline Reaches Decision Points in 2026. Lundbeck's bocunebart Phase 2b IV data (H1 2026) and subsequent Phase 3 go/no-go decision (H2 2026) will determine whether PACAP blockade becomes the second validated migraine-specific target after CGRP. Slate Medicines' $130M-funded SLTE-1009 enters Phase 1 mid-2026, adding competitive pressure. The ongoing CGRP cardiovascular safety discussion may accelerate interest in orthogonal migraine mechanisms for high-risk patient populations.

H2 2026 Delivers Critical Neuroimmunology Readouts. Dianthus claseprubart Phase 3 CAPTIVATE interim data in CIDP (~480 patients) and Phase 2 MoMeNtum topline results in MMN both expected H2 2026, potentially expanding the complement inhibitor market beyond gMG. Voyager's VY7523 anti-tau antibody tau PET imaging data (H2 2026) will provide the first human pharmacodynamic proof-of-concept for a tau-targeting biologic administered intravenously.

AAN Annual Meeting (April 2026) and AHS Annual Meeting (June 2026) Set the Narrative. AAN will feature fenebrutinib head-to-head data, tavapadon long-term updates, and CGRP real-world evidence across all verticals. AHS will be the primary venue for PACAP pipeline updates and the evolving CGRP safety risk-benefit discussion. Both conferences shape prescriber and payer sentiment for the remainder of the year.